Reduced‐intensity conditioning haematopoietic cell transplantation for haemophagocytic lymphohistiocytosis: an important step forward
Open Access
- 28 June 2011
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 154 (5), 556-563
- https://doi.org/10.1111/j.1365-2141.2011.08785.x
Abstract
Haemophagocytic lymphohistiocytosis (HLH) is a life‐threatening immunodeficiency characterized by severe systemic hyper‐inflammatory responses to infectious or other triggers of the immune system. In many patients, the underlying cause of HLH is a genetic defect leading to defective CD8+ T cell and natural killer cell granule‐mediated cytotoxicity. The treatment of HLH consists principally of immune suppression followed by allogeneic haematopoietic cell transplantation (HCT) to cure the underlying defect and prevent relapse of HLH. Initial treatment regimens consist of steroids coupled with either etoposide or antithymocyte globulin, ± ciclosporin. Complete responses are observed in only 50–75% of patients and even after a complete response, relapse and death still occur. The only definitive, long‐term cure for patients with genetic forms of HLH is allogeneic HCT. Unfortunately, allogeneic HCT for patients with HLH is often complicated by critical illness, extensive organ involvement, active infections, or refractory HLH. For these reasons, patients are unusually prone to developing transplant‐related toxicities and complications. In recent years, great strides have been made with regard to the care and transplantation of patients with HLH. Here we review the current state of the treatment of patients with HLH with allogeneic HCT, highlighting the important steps forward that have been made with reduced‐intensity conditioning.Keywords
This publication has 42 references indexed in Scilit:
- Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosisBlood, 2011
- X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the diseaseBlood, 2011
- XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative diseasePublished by American Society of Hematology ,2010
- Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cellsJCI Insight, 2009
- Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis in JapanPediatric Blood & Cancer, 2009
- Familial Hemophagocytic Lymphohistiocytosis Type 5 (FHL-5) Is Caused by Mutations in Munc18-2 and Impaired Binding to Syntaxin 11American Journal of Human Genetics, 2009
- The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosisBone Marrow Transplantation, 2008
- Munc13-4 Is Essential for Cytolytic Granules Fusion and Is Mutated in a Form of Familial Hemophagocytic Lymphohistiocytosis (FHL3)Cell, 2003
- Perforin Gene Defects in Familial Hemophagocytic LymphohistiocytosisScience, 1999
- Allogeneic bone marrow transplantation for erythrophagocytic lymphohistiocytosisThe Journal of Pediatrics, 1986